Signs that CTIX is already working with a potential partner on K.
K-OC was originally planned for a Phase 1b/2 trial in combination with doxorubicin in June. After Dr. B joined the company, now it's planned for a Phase 2a POC trial designed to show the modulation of p53 in tumors, with K for three weeks followed by doxorubicin for four cycles.
This is what management said in the Q&A yesterday.
"It is more prudent for us to take into consideration what a potential partner wants and make that happen."
"Concerning Kevetrin, a successful short trial identifying p53 modulation in the tumor and a successful development of a formulation for frequent dosing is needed."
A K partnership could be sooner than we thought.
K-OC was originally planned for a Phase 1b/2 trial in combination with doxorubicin in June. After Dr. B joined the company, now it's planned for a Phase 2a POC trial designed to show the modulation of p53 in tumors, with K for three weeks followed by doxorubicin for four cycles.
This is what management said in the Q&A yesterday.
"It is more prudent for us to take into consideration what a potential partner wants and make that happen."
"Concerning Kevetrin, a successful short trial identifying p53 modulation in the tumor and a successful development of a formulation for frequent dosing is needed."
A K partnership could be sooner than we thought.
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
